Clinical Microbiology and Infection最新文献

Background: Data sharing accelerates scientific progress and improves evidence quality. Even though journals and funding institutions require investigators to share data, only a small part of studies made their data publicly available upon publication. The procedures necessary to share retrospective data for reuse in secondary data analysis projects can be cumbersome.

Objectives: Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance is a European research project that aims to develop mathematical models and an epidemiological repository to assess the impact of vaccines and monoclonal antibodies on antimicrobial resistance (AMR). To accomplish the project aim, Work Package 3 was responsible for gathering historical anonymized individual patient datasets.

Sources: Through a systematic search we have identified 108 eligible studies for data sharing; of which eight have completed all legal requirements and shared their datasets, with data from four infectious syndromes and seven resistant pathogens. The AMR data gathered in Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance project are publicly available in European Clinical Research Alliance on Infectious Disease epidemiology network platform (https://epi-net.eu/primavera/about/anonymized-individual-patient-data/).

Content: Challenges and possible solutions in data sharing activities were mapped and discussed: lack of researchers' interest in sharing data, cumbersome ethical and legal requirements, laborious data management procedures, specific requirements for public data access, insufficient training and funding.

Implications: We expect that experience gained in this project can be useful to improve data sharing; and that the datasets gathered can be used in future AMR projects.

Background: Healthcare-associated infections (HAIs) remain a significant challenge worldwide, and the use of multimodal strategies is recommended by the World Health Organization (WHO) to enhance infection prevention.

Objectives: To update the systematic review on facility-level infection prevention and control (IPC) interventions on the WHO Core Component of using multimodal strategies.

Methods: Data Sources: Medline (via PubMed), EMBASE, CINAHL, and the Cochrane library.

Study eligibility criteria: Randomized controlled studies (RCTs), interrupted time series (ITS), and before-after studies in acute care settings, from 24 November 2015 to 30 June 2023.

Participants: Both paediatric and adult populations.

Interventions: IPC interventions implemented with at least three WHO multimodality elements.

Primary outcomes: HAI, HAI caused by antimicrobial-resistant microorganisms, and hand hygiene (HH) compliance.Assessment of Risk of Bias: Effective practice and organisation of care (EPOC) and integrated quality criteria for review of multiple study designs (ICROMS) tools.Methods of data Synthesis: Descriptive data synthesis.

Results: Of 5678 identified titles and abstracts, 32 publications were eligible for data extraction and analysis. Five non-controlled before-after studies (NCBA) were excluded due to an insufficient ICROMS score. Of the remaining 27 studies, nine reported on the effect of multimodal strategies to reduce device-associated HAIs, four on surgical site infections, eight on infections due to AMR and six on HH compliance. Eleven were controlled studies (RCTs or controlled before-after studies (CBAs)), nine ITS and seven NCBA studies. Twenty-two of the studies originated from high-income countries and the overall quality was medium to low. Twenty studies showed either significant HAI-reductions or HH improvement.

Conclusion: Most studies demonstrate a significant effect on HAI prevention and HH improvement after applying a multimodal strategy. However, the quality of evidence remains low to moderate with few studies from low- or middle-income countries. Future research should focus on higher quality studies in resource limited settings.

Objectives: Because fungal infections (FI) are frequently encountered by pathologists, it is crucial to improve fungal diagnosis on formalin-fixed paraffin-embedded tissues (FT). We aimed to investigate if a histomolecular approach using targeted-massive parallel sequencing (MPS) could help detect and identify fungi on FT when no mycological diagnosis is available on fresh tissue.

Methods: Forty-nine FT from 48 patients with histopathological FI diagnosis but without mycological identification were retrospectively included. Histopathology defined the fungal pattern and the tissue injuries. Panfungal PCRs were performed using ITS-3/ITS-4 and MITS-2A/MITS-2B primers. Amplicons were sequenced using Sanger sequencing and targeted-MPS. Probabilities of fungal identification for both sequencing techniques and both primers were compared.

Results: The median age was 57 years (Q1: 47; Q3: 64). Fungal cultures were performed in 22/49 (44.9%) samples but failed to identify the pathogenic fungi. Fungal identification by Sanger sequencing was successful in 17/49 (34.7%; [0.214-0.480]) FT; the probability of fungal identification was 32.7% (16/49; [0.195-0.458]) for ITS-3/ITS-4; and 22.4% (11/49; [0.108-0.341]) for MITS-2A/MITS-2B. Targeted-MPS was successful in 35/49 (71.4%; [0.588-0.841]) samples; the probability of fungal identification was 59.2% (29/49; [0.454-0.729]) for ITS-3/ITS-4 primers and 61.2% (30/49; [0.476-0.749]) for MITS-2A/MITS-2B. The probability of fungal identification by targeted-MPS (35/49 [71.4%]) was significantly higher than that of Sanger sequencing (17/49 [34.7%]; p < 0.0001). We assessed that this approach could have optimized care for 22/48 (45.8%) patients.

Discussion: Integrated histomolecular diagnosis using targeted-MPS could secure diagnosis and help clinicians prescribe the most appropriate antifungal therapy in the absence of mycological identification.

Background: The World Health Organization (WHO) recommends antiretroviral therapy (ART) containing two nucleoside reverse transcriptase inhibitors (NRTIs) as backbone. WHO recommends tenofovir disoproxil fumarate combined with lamivudine or emtricitabine as first line in pregnancy, and zidovudine, abacavir or tenofovir alafenamide, combined with lamivudine or emtricitabine, as alternatives.

Objectives: Evaluate risk of adverse perinatal outcomes in pregnant women living with HIV (WLHIV) receiving different NRTIs.

Data sources: Medline, CINAHL, Global Health, EMBASE.

Study eligibility criteria: Cohort studies.

Participants: Pregnant WLHIV.

Interventions: ART regimes containing different NRTI drugs.

Assessment of risk of bias: Newcastle-Ottawa Scale and GRADE.

Methods of data synthesis: Random-effects meta-analysis.

Results: 22 cohort studies including 124,478 WLHIV met the eligibility criteria. ART containing tenofovir disoproxil fumarate was associated with lower risk of preterm birth (Risk Ratio 0.89; 95% confidence interval 0.81-0.97), very preterm birth (0.58; 0.40-0.86), small for gestational age (0.76; 0.59-0.98), very small for gestational age (0.60; 0.48-0.73), stillbirth (0.49; 0.31-0.78), and neonatal death (0.61; 0.40-0.93), compared to ART not containing tenofovir disoproxil fumarate. ART containing zidovudine was associated with increased risk of very preterm birth (1.59; 1.01-2.49), small for gestational age (1.33; 1.03-1.70), very small for gestational age (1.63; 1.25-2.13), stillbirth (2.23; 1.10-4.55), and neonatal death (1.65; 1.08-2.52), compared to ART not containing zidovudine. For ART regimens also containing either lamivudine or emtricitabine, zidovudine was associated with increased risk of very preterm birth (1.62; 1.04-2.52), small for gestational age (1.52; 1.28-1.82), very small for gestational age (1.68; 1.36-2.06), stillbirth (2.19; 1.03-4.67), and neonatal death (1.65; 1.08-2.52), compared to ART containing tenofovir disoproxil fumarate. Abacavir was not associated with adverse perinatal outcomes. Tenofovir alafenamide was not associated with low birth weight compared to tenofovir disoproxil fumarate.

Conclusion: Tenofovir disoproxil fumarate is associated with a lower risk of adverse perinatal outcomes, whereas zidovudine is associated with an increased risk of perinatal outcomes. Abacavir is not associated with adverse perinatal outcomes. Our findings support current WHO guidelines.